The University of Chicago Header Logo

Connection

Alexander Pearson to Cell Line, Tumor

This is a "connection" page, showing publications Alexander Pearson has written about Cell Line, Tumor.
Connection Strength

0.617
  1. Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clin Cancer Res. 2020 02 01; 26(3):608-622.
    View in: PubMed
    Score: 0.110
  2. PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. J Exp Clin Cancer Res. 2025 Jan 11; 44(1):11.
    View in: PubMed
    Score: 0.040
  3. Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. Cell Rep. 2024 08 27; 43(8):114551.
    View in: PubMed
    Score: 0.038
  4. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019.
    View in: PubMed
    Score: 0.037
  5. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. Oral Oncol. 2024 Feb; 149:106688.
    View in: PubMed
    Score: 0.037
  6. The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death Dis. 2021 10 23; 12(11):988.
    View in: PubMed
    Score: 0.032
  7. In Silico Models Accurately Predict In Vivo Response for IL6 Blockade in Head and Neck Cancer. Cancer Res. 2020 04 01; 80(7):1451-1460.
    View in: PubMed
    Score: 0.028
  8. ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clin Cancer Res. 2019 06 01; 25(11):3392-3403.
    View in: PubMed
    Score: 0.026
  9. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 03 01; 25(5):1588-1600.
    View in: PubMed
    Score: 0.026
  10. Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. Stem Cells. 2019 02; 37(2):257-269.
    View in: PubMed
    Score: 0.026
  11. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncol. 2018 12; 87:21-28.
    View in: PubMed
    Score: 0.026
  12. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5561-5572.
    View in: PubMed
    Score: 0.023
  13. EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells. Cancer Res. 2016 11 01; 76(21):6396-6409.
    View in: PubMed
    Score: 0.022
  14. 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2017 May 15; 23(10):2516-2527.
    View in: PubMed
    Score: 0.022
  15. Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res. 2017 Feb 15; 23(4):1036-1048.
    View in: PubMed
    Score: 0.022
  16. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016 04 15; 76(8):2301-13.
    View in: PubMed
    Score: 0.022
  17. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016 07 15; 22(14):3550-9.
    View in: PubMed
    Score: 0.021
  18. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas. Oncotarget. 2015 Sep 29; 6(29):26633-50.
    View in: PubMed
    Score: 0.021
  19. Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget. 2015 Sep 08; 6(26):22822-35.
    View in: PubMed
    Score: 0.021
  20. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011 Aug 15; 17(16):5275-86.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.